Nasus Pharma Ltd. (NSRX) is a publicly traded the market company. As of May 21, 2026, NSRX trades at $2.74 with a market cap of $32.20M and a P/E ratio of 0.00. NSRX moved +2.20% today. Year to date, NSRX is -70.05%; over the trailing twelve months it is flat. Its 52-week range spans $1.98 to $9.99. Analyst consensus is buy with an average price target of $18.00. Rallies surfaces NSRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nasus Pharma Reports $4.3M Cash, NS002 Phase 2 Spurs Q4 2026 Pivotal Study: NS002 Phase 2 topline data showed statistically significant faster time to therapeutic threshold and higher epinephrine absorption versus EpiPen, driving a pivotal study to start in Q4 2026 with a readout by Q1 2027. The company ended 2025 with $4.3M cash, raised via $15M private placement to fund operations into mid-2027.
| Metric | Value |
|---|---|
| Price | $2.74 |
| Market Cap | $32.20M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.99 |
| 52-Week Low | $1.98 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover NSRX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.00.